Kenneth Backman, MD
Allergy & Immunology · Fairfield, CTNPI 1174595847
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AstraZeneca at 54.1% of the total. 2025 is the largest year on record at $5,262, 4.4 times the $1,185 reported in 2019.
Across 268 payments — averaging $44.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Kaleo, Inc.$1K
- GSK$1K
- Genentech USA, Inc.$411
- Boehringer Ingelheim$365
- Sanofi$256
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$6,77557%
- Food & beverage$5,03642%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $6,419 |
| Kaleo, Inc. | 10 | $1,404 |
| GSK | 73 | $1,315 |
| Genentech USA, Inc. | 24 | $411 |
| Boehringer Ingelheim | 19 | $365 |
| Sanofi | 13 | $256 |
| Pfizer | 13 | $214 |
| Optinose US, Inc. | 12 | $214 |
| CSL Behring | 10 | $213 |
| Alk-abello, Inc | 9 | $191 |
| Novartis | 6 | $118 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $102 |
| Covis Pharma GmbH | 4 | $93 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| Merck | 4 | $73 |
| Amgen(2 entities) | 2 | $54 |
| LEO Pharma Inc. | 2 | $51 |
| Biocryst Pharmaceuticals, Inc. | 3 | $49 |
| Incyte Corporation | 2 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Circassia Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,856 in reported general payments places this provider in the 80th percentile of 54 allergy & immunology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 14 | $52,388 |
| TezspireTezepelumab-Ekko | 11 | $45,542 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $22,714 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,529 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,372 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,186 |
| Epinephrine | 29 | $4,605 |
| Mometasone Furoate | 33 | $3,665 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 18 | $1,927 |
| Montelukast Sodium | 47 | $654 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $586 |
| Fluticasone Propionate | 30 | $326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $6,419 | $59,10035 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,315 | $36,24347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 54 allergy & immunology providers in Connecticut.
Other allergy & immunology in Fairfield
- Katherine BloomFairfield$4K
- Sara DeverFairfield$3K
- Aimee Altschul LatzmanFairfield$3K
- Gavin SchwarzWest Hartford$262K
- Christina PriceNew Haven$96K
- Florence HsuNorth Haven$84K
- Jason LeeWest Hartford$30K
- Birur ChandraEast Haven$15K
- Michael KingTrumbull$14K
- Prasad SrinivasanGlastonbury$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.